Tiago Fauth
Stock Analyst at Wells Fargo
(3.15)
# 1,061
Out of 5,127 analysts
152
Total ratings
44.83%
Success rate
1.6%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $148.55 | +46.08% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $13.59 | +32.45% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $473.20 | -12.51% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.83 | +71.53% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $72.14 | +1.19% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $40.54 | -23.53% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $322.98 | +22.30% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $24.20 | +168.60% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $72.47 | +4.87% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.27 | +32.83% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $21.05 | +379.81% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.16 | +158.62% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $17.15 | +51.60% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.30 | +18.88% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $74.75 | +0.33% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $13.96 | +344.13% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $224.19 | -60.30% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $30.06 | +69.66% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $59.66 | +101.14% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $26.68 | -85.01% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.64 | +430.30% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $83.63 | +258.74% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $7.84 | +231.63% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.16 | +786.08% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $22.58 | +258.72% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.20 | +3,886.05% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.39 | +907.19% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $2.55 | +1,233.33% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $21.52 | +597.03% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $42.98 | -32.53% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.73 | +651.45% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.78 | +630.34% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.84 | +136.71% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $833.16 | -59.19% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $364.65 | -28.97% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $148.55
Upside: +46.08%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $13.59
Upside: +32.45%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $473.20
Upside: -12.51%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.83
Upside: +71.53%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $72.14
Upside: +1.19%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $40.54
Upside: -23.53%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $322.98
Upside: +22.30%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $24.20
Upside: +168.60%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $72.47
Upside: +4.87%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.27
Upside: +32.83%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $21.05
Upside: +379.81%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.16
Upside: +158.62%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $17.15
Upside: +51.60%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.30
Upside: +18.88%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $74.75
Upside: +0.33%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $13.96
Upside: +344.13%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $224.19
Upside: -60.30%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $30.06
Upside: +69.66%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $59.66
Upside: +101.14%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $26.68
Upside: -85.01%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.64
Upside: +430.30%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $83.63
Upside: +258.74%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $7.84
Upside: +231.63%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.16
Upside: +786.08%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $22.58
Upside: +258.72%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.20
Upside: +3,886.05%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.39
Upside: +907.19%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $2.55
Upside: +1,233.33%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $21.52
Upside: +597.03%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $42.98
Upside: -32.53%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.73
Upside: +651.45%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.78
Upside: +630.34%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.84
Upside: +136.71%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $833.16
Upside: -59.19%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $364.65
Upside: -28.97%